Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Exclusion Criteria

• •1. CNV or macular edema in the study eye secondary to any causes other than AMD
• •2. Subfoveal fibrosis or atrophy in the study eye
• •3. Any condition in the investigator's opinion that could limit VA improvement in the study eye
• •4. Advanced glaucoma or history of secondary glaucoma in the study eye
• •5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months
• •6. History of intraocular surgery in the study eye within 12 weeks prior to randomization
• •7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6
• •8. Prior treatment with gene therapy
• •1. CNV or macular edema in either eye secondary to any causes other than AMD
• •2. Subfoveal fibrosis or atrophy in either eye
• •3. Any condition in the investigator's opinion that could limit VA improvement in either eye
• •4. Advanced glaucoma or history of secondary glaucoma in either eye
• •5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months
• •6. History of intraocular surgery in either eye within 12 weeks prior to randomization
• •7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6.
• •8. Prior treatment with gene therapy (\*) For previously treated crossover participants, criteria apply to the eye not treated in the main study only.